“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have […]
BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30,2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its […]